A new gene identified in P. aeruginosa could act as a prognostic biomarker and treatment target for patients with bloodstream infections.
Browsing: Basic > Drug Development
E. coli’s internal bomb – the toxin-antitoxin system – could be triggered to make bacteria turn on themselves, offering a new target for antimicrobial approaches in drug design.
Our sister site, MedChemNet, spoke to Joseph Hargan-Calvopiña, Program Manager at BIO Ventures for Global Health, to find out more about their work in global drug development for neglected tropical diseases.
We recently spoke about the ins and outs of funding and financing for antimicrobials with John Rex, who shares his thoughts on the issues underlying antibiotic development, the recent DRIVE-AB report, and where we might be 10 years in the future.
We look at some of the highlights of our Twitter chat (#TalkTB), where we questioned Madhukar Pai, Nandita Venkatesan and Jacob Creswell about all things tuberculosis – from diagnosis to social stigma.
Partnership announcements and promising trial data reported at the 2018 Conference on Retroviruses and Opportunistic Infections, take a look at our round-up of the latest industry headlines.
A small clinical trial has demonstrated that an IL-7 drug that revs up the body’s immune system holds promise in sepsis patients, potentially offering a new approach to improve survival rates.
We take a look at the key microbiome therapeutics currently in the clinical pipeline for recurrent C. difficile infections and their prospects for the treatment of this disease in the future.
Listen to our podcast rounding up the top news stories of the week, including the measles vaccine and the sexual transmission of Zika.
In this article, the authors test ocellatin peptides against one of the most concerning priority pathogens, Pseudomonas aeruginosa.